Tissue-Lysate Kits Now Available for Tumor Proteomic Profiling

The procedure is based on detection of an antibody to a protein of interest that is applied to the kit's pre-printed tissue lysate array, and which binds to the target protein in the lysates. Next, a species-specific, biotin-labeled secondary antibody is added for detection of the primary antibody bound to the protein of interest. The antibody-biotin complex is then visualized using APiX chromogenic reagents, which allow for the detection of any biotinylated molecule. APiX chromogenic reagents generate light grey-to-black spots that are visible to the naked eye and can be scanned with the "Proteomics Multi-System” using a patented, gold-catalyzed silver deposition that typically achieves measurably improved sensitivity compared to fluorescence detection. Results are obtained in less than five hours.

Currently available assays cover a range of cancers from those of the liver, prostate, and ovary to those of the stomach, thyroid, and bladder as well as leukemia and other blood cancers.

"This product launch continues to expand the portfolio of APiX kits to include clinically relevant tissue-lysate arrays,” said Alex Vodenlich, president and CEO of Gentel Biosciences. "We are responding to the market's need for technologies that enable rapid screening of patient specimens for the abundance of potential protein biomarkers. This ability has broad applications in biological and biomedical research and is ideally suited for screening known and novel cancer-related protein biomarkers. The product line is relevant for use in testing cancer-research hypotheses with a large number of well characterized clinical-case samples, as statistical significance confirmation is a key validation step in late stage in vitro studies.”

Related Links:
Gentel Biosciences
Protein Biotechnologies